| Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer (NCT06848439) | Jiangsu Cancer Institute & Hospital | 2025-06-15 |
| Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies） (NCT07007767) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-06-15 |
| Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients (NCT06409819) | University of California, San Diego | 2025-06-15 |
| Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers (NCT07033585) | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 2025-06-15 |
| QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors (NCT06892925) | Eastern Hepatobiliary Surgery Hospital | 2025-06-14 |
| Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC (NCT06745882) | H. Lee Moffitt Cancer Center and Research Institute | 2025-06-13 |
| ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression (NCT07327034) | Abbisko Therapeutics Co, Ltd | 2025-06-13 |
| A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) (NCT06789913) | Relay Therapeutics, Inc. | 2025-06-13 |
| Study of ZG005 in Patients With Advanced Solid Tumors (NCT06927687) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-06-13 |
| REgulatory T Cell Therapy to Achieve Immunosuppression REduction (NCT06552169) | Singulera Therapeutics Inc. | 2025-06-13 |
| Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke (NCT06857487) | Dongzhimen Hospital, Beijing | 2025-06-13 |
| Feasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study (NCT07051980) | Zhejiang University | 2025-06-12 |
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma (NCT06620302) | Children's Oncology Group | 2025-06-12 |
| TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate (NCT06513286) | Michael Hoelscher | 2025-06-12 |
| Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) (NCT06577441) | National Cancer Institute (NCI) | 2025-06-12 |
| Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery (NCT07036510) | EyeD Pharma | 2025-06-12 |
| A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer (NCT06990880) | GlaxoSmithKline | 2025-06-12 |
| NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (NCT06919666) | University of Colorado, Denver | 2025-06-12 |
| Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors (NCT06975410) | Yuhan Corporation | 2025-06-12 |
| Efficacy Testing of a Multi-Level Family Planning Intervention (NCT06923189) | Boston College | 2025-06-12 |
| Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis (NCT06668493) | Ferring Pharmaceuticals | 2025-06-12 |
| Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial (NCT06405607) | University of Iowa | 2025-06-12 |
| Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors (NCT06926751) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-06-12 |
| FMXIN002 in Patients at Risk of Anaphylaxis (NCT07045701) | Nasus Pharma | 2025-06-12 |
| COMBO Endoscopy Oropharyngeal Airway in Sedated Endoscopic Retrograde Cholangiopancreatography for Patients (NCT07012772) | Zhejiang University | 2025-06-12 |
| ConnectedNest: a Digital Platform Connecting Individuals With Cancer to Social Care (NCT06559228) | University of Minnesota | 2025-06-12 |
| Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 (NCT07024394) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2025-06-12 |
| Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (NCT07075718) | Glaukos Corporation | 2025-06-12 |
| A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NCT06975748) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2025-06-12 |
| Unique Treatment of Oncology Pain in Advanced Cancer (NCT06533657) | ZYUS Life Sciences Inc. | 2025-06-12 |
| A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) (NCT06885034) | GlaxoSmithKline | 2025-06-11 |
| Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy (NCT07014202) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-06-11 |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] (NCT06783647) | Nanjing Leads Biolabs Co.,Ltd | 2025-06-11 |
| P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease (NCT06489340) | ZyVersa Therapeutics, Inc. | 2025-06-11 |
| ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer (NCT06902272) | University of Miami | 2025-06-11 |
| PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients (NCT06906822) | Grupo Español Multidisciplinar de Melanoma | 2025-06-10 |
| Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer (NCT06783140) | University Health Network, Toronto | 2025-06-10 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) (NCT06703073) | PPD Development, LP | 2025-06-10 |
| To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH (NCT07016633) | Changchun Intellicrown Pharmaceutical Co. LTD | 2025-06-10 |
| Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma (NCT07014150) | Peking Union Medical College Hospital | 2025-06-10 |
| A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma (NCT07010120) | West China Hospital | 2025-06-10 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart (NCT06701669) | PPD Development, LP | 2025-06-10 |
| Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury (NCT06954740) | Chinese PLA General Hospital | 2025-06-10 |
| Shorter and Safer Treatment Regimens for Latent TB (NCT06498414) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2025-06-10 |
| Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost (NCT06627738) | Centre Antoine Lacassagne | 2025-06-10 |
| Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (NCT06972641) | Ruijin Hospital | 2025-06-10 |
| A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer (NCT06978114) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-06-10 |
| HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma (NCT06858735) | M.D. Anderson Cancer Center | 2025-06-10 |
| A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus (NCT06575426) | Otsuka Pharmaceutical Factory, Inc. | 2025-06-10 |
| Combined Oral Contraceptive Pill and Resistance Starch (NCT06852365) | University of Pennsylvania | 2025-06-10 |
| Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors (NCT06993844) | Ensem Therapeutics | 2025-06-10 |
| Peripheral Magnetic Stimulation With Balance Training to Decrease Fall Risks in Diabetic Polyneuropathy (NCT07000214) | Queen Savang Vadhana Memorial Hospital, Thailand | 2025-06-10 |
| A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC (NCT06971614) | ImmVira Pharma Co. Ltd | 2025-06-09 |
| Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease (NCT06969807) | Chinese PLA General Hospital | 2025-06-09 |
| Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) (NCT06676579) | Mayo Clinic | 2025-06-09 |
| A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations (NCT06947811) | Sun Yat-sen University | 2025-06-09 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma (NCT06761677) | SymBio Pharmaceuticals | 2025-06-09 |
| Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer (NCT06873763) | STCube, Inc. | 2025-06-09 |
| Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer (NCT06990542) | University of California, San Diego | 2025-06-09 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease (NCT06808984) | Celgene | 2025-06-09 |
| A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT06907615) | Shanghai Henlius Biotech | 2025-06-09 |
| Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas (NCT06865677) | National Cancer Institute (NCI) | 2025-06-09 |
| ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NCT06902558) | Calico Life Sciences LLC | 2025-06-09 |
| Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis (NCT06998056) | Arcutis Biotherapeutics, Inc. | 2025-06-09 |
| Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) (NCT06956235) | Merck Sharp & Dohme LLC | 2025-06-09 |
| Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder) (NCT06795659) | The University of Texas Health Science Center at San Antonio | 2025-06-09 |
| A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs (NCT07069569) | Ausper Biopharma Co., Ltd. | 2025-06-08 |
| Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer (NCT07026149) | Ruijin Hospital | 2025-06-08 |
| A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure (NCT07446491) | Chongqing Peg-Bio Biopharm Co., Ltd. | 2025-06-06 |
| XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer (NCT06959641) | Jochen Lorch | 2025-06-06 |
| A Study of S-892216 in Participants With COVID-19 (NCT06928051) | Shionogi | 2025-06-06 |
| A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma (NCT06670105) | M.D. Anderson Cancer Center | 2025-06-06 |
| First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma (NCT06797999) | Adcendo ApS | 2025-06-05 |
| Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer (NCT06914440) | Xijing Hospital | 2025-06-05 |
| Ketamine Effects on Learning In Eating Disorders (NCT06736769) | Amanda Downey, MD | 2025-06-05 |
| A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer (NCT06891833) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-06-05 |
| A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema (NCT06962839) | Boehringer Ingelheim | 2025-06-05 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity (NCT06782490) | Celgene | 2025-06-05 |
| Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial (NCT06974370) | University of Vermont Medical Center | 2025-06-05 |
| Digoxin In NASH (CODIN) (NCT06588699) | Yale University | 2025-06-05 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (NCT06317662) | National Cancer Institute (NCI) | 2025-06-05 |
| Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (NCT06461988) | Stanford University | 2025-06-05 |
| A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (NCT06847867) | GlaxoSmithKline | 2025-06-05 |
| A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults (NCT06997627) | GC Biopharma Corp | 2025-06-05 |
| Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD (NCT06969573) | University of Alberta | 2025-06-05 |
| Outpatient Epcoritamab in Large B-cell Lymphoma (NCT06811272) | Massachusetts General Hospital | 2025-06-05 |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) (NCT07038343) | Avenzo Therapeutics, Inc. | 2025-06-04 |
| MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer (NCT06998342) | University of Vermont Medical Center | 2025-06-04 |
| Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome (NCT06895473) | OHSU Knight Cancer Institute | 2025-06-04 |
| Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis (NCT07712536) | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | 2025-06-04 |
| A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (NCT06167785) | University Health Network, Toronto | 2025-06-04 |
| Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases (NCT07011849) | M.D. Anderson Cancer Center | 2025-06-04 |
| Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models (NCT07005414) | Fei Li | 2025-06-04 |
| Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors (NCT06947291) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-06-04 |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (NCT06770582) | National Cancer Institute (NCI) | 2025-06-03 |
| Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） (NCT07076693) | Shanghai Chest Hospital | 2025-06-03 |
| The Role of Vitamin K on Knee Osteoarthritis Outcomes (NCT06385275) | Boston University | 2025-06-03 |
| Comparison Between a Rush and a Conventional Oral Immunotherapy Protocol to Treat Cow's Milk and Hen´s Egg Allergy. CompITO Study (NCT06976775) | Pablo Rodríguez del Rio | 2025-06-03 |
| EF-M2 (Immutalon) Multiple Ascending Dose Study in Moderate-to-Severe Rheumatoid Arthritis (NCT07349420) | S.LAB (SOLOWAYS) | 2025-06-03 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis (NCT06672978) | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | 2025-06-03 |